[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"N.N. Alexandrov National Cancer Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,73,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629244","phase-2-pd-1-programmed-death-1-versus-pd-l1-programmed-death-ligand-1-immune-check-point-inhibitors-combined-with-chemotherapy-with-or-without-bevacizumab-in-patients-with-metastatic-persistent-or-recurrent-cervical-cancer-100629244",false,"NCT07472153","PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","To Validate, Develop and Implement The Scope of Medical Care for Metastatic, Persistent and Recurrent Cervical Cancer Using The Method of Chemoimmunotargeted Therapy","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis.\n* One of the forms of the cervical cancer:\n\n  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);\n  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);\n  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).\n* Availability of material for determining PD-L-1 expression for immunotherapy candidates.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* No contraindications to chemotherapy, immunotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.","FEMALE","18 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.",[28,29,30],"Metastatic Cervical Cancer","Persistent Cervical Cancer","Recurrent Cervical Cancer","RECRUITING","2026-05-26",{"date":34,"type":35},"2026-05-28","ACTUAL",{"date":37,"type":35},"2025-07-01",{"date":39,"type":21},"2033-06-30",{"name":41,"class":42},"N.N. Alexandrov National Cancer Centre","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100633294","real-world-practice-with-academic-anti-cd19-car-t-cell-therapy-in-relapserefractory-b-cell-lymphoma-100633294","NCT07524816","Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse\u002FRefractory B-cell Lymphoma","Treatment Method of Patients With Refractory and Relapsed CD-19 Positive Leukemia and Lymphoma Using Academic Anti-CD19 CAR-T Human Cells","Inclusion Criteria:\n\n* age ≥18 years,\n* relapsed or refractory LBCL,\n* confirmed CD19 expression in tumor tissue,\n* prior exposure to at least one line of anti-tumor therapy\n\nExclusion Criteria:\n\n* pregnancy,\n* active hepatitis B or C infection, HIV infection,\n* naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%","ALL","80 Years",{"count":54,"type":21},76,"3 Months","OBSERVATIONAL","Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed\u002Frefractory large B-cell lymphomas (R\u002FR LBCLs) since 2018. However, high cost of commercial products limits their application in real-world clinical practice. Academic approach to manufacturing CAR-T cell products can reduce the costs and improve availability and affordability of this therapy option. The aim of the present study is assess the efficacy and safety of the use of academic CAR-T cell products in r\u002Fr LBCL patients.This prospective observational study with r\u002Fr LBCL patients treated in the NN Alexandrov National Cancer Centre of Belarus. The CAR-T cell product was manufactured using lentiviral vector encoding anti-CD19 CAR.",[59],"Large B-Cell Lymphoma (LBCL)",[61,62,63,64],"academic CAR-T cell products","r\u002Fr large B-cell lymphomas","efficacy","safety","2026-04-09",{"date":67,"type":35},"2026-04-13",{"date":69,"type":35},"2021-06-01",{"date":71,"type":21},"2029-01-01",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":92,"locationsCount":43},"100629243","phase-2-parp-poly-adp-ribose-polymerase-inhibitor-with-or-without-angiogenesis-inhibitor-in-homologous-recombination-deficient-primary-ovarian-cancer-fallopian-tube-cancer-or-primary-peritoneal-cancer-100629243","NCT07472140","PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.\n* Presence of homologous recombination deficiency (HRD).\n* No contraindications to chemotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.\n* Disease progression during treatment.",{"count":20,"type":21},[24,25],"This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.",[84,85,86],"Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","2026-03-11",{"date":89,"type":35},"2026-03-16",{"date":37,"type":35},{"date":39,"type":21},{"name":41,"class":42},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":100,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":43},"100616698","limited-versus-extended-lymph-node-dissection-during-radical-prostatectomy-in-patients-with-localized-or-locally-advanced-prostate-cancer-100616698","NCT07308990","Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer","To Develop and Implement a Method for Optimizing the Volume of Lymph Node Dissection in Radical Surgical Treatment of Localized or Locally Advanced Prostate Cancer","Inclusion Criteria:\n\n1. Age over 18 years.\n2. Histologically confirmed localized or locally advanced prostate cancer (adenocarcinoma without a neuroendocrine component).\n3. No evidence of metastatic spread of the tumor\n4. Local resectability of the tumor according to digital rectal examination and\u002For CT and\u002For MRI of the pelvis\n5. Patients are suitable for radical prostatectomy based on their comorbidities and life expectancy.\n6. Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Presence of another active malignant invasive neoplasm.\n2. Contraindication to pelvic lymph node dissection (e.g., history of radiation therapy to the pelvis).\n3. The evidence of metastases in regional lymph nodes according to preoperative examination data (including PET\u002FCT with PSMA).\n4. Severe concomitant disease limiting participation in the study.","MALE",{"count":102,"type":21},800,[104],"NA","This is a randomized controlled study assessing outcome of low (no or limited) versus high (limited or extended) extent of lymph node dissection in addition to radical prostatectomy in patients with operable localized or locally advanced prostate cancer.",[107],"Prostate Cancer Patients Undergoing Radical Prostatectomy",[109,110,111],"prostate cancer","lymph node dissection","radical prostatectomy","2025-12-15",{"date":114,"type":35},"2025-12-30",{"date":116,"type":35},"2025-10-29",{"date":118,"type":21},"2032-05-30",{"name":41,"class":42},""]